AKTS

16.1501.52%
PL

Paul L. Feldman

Chief Scientific Officer

Dr. Paul L. Feldman, Ph.D. is Chief Scientific Officer of Aktis Oncology Inc. since December 2020. Dr. Feldman has been Head of Discovery & Translational Medicine of Intarcia Therapeutics, Inc. since September 2015. Dr. Feldman was Cofounder of Phoundry Pharmaceuticals, Inc and served as its Chief Executive Officer and Director. Dr. Feldman then spent five years at Intarcia on the executive management team as Head of Discovery and Translational Medicine leading the discovery and development of novel peptide therapeutics to treat metabolic disease until December 2020. Prior to his work at Phoundry, Dr. Feldman worked for GlaxoSmithKline, ultimately as a senior vice president and some of his accomplishments included: contributing to the discovery and development of multiple medicines, leading national and international multi-disciplinary discovery and early development groups, managing several key multi-national business collaborations and serving as the head for GlaxoSmithKline’s Research Triangle Park site. Dr. Feldman has more than 100 scientific disclosures (patents, scientific articles, book chapters and invited lectures) and has been an adjunct Professor of Chemistry for Duke and North Carolina State Universities. Dr. Feldman also serves on the board of directors of the Chordoma Foundation. He has served in multiple leadership roles for the executive committee of the Division of Organic Chemistry of the American Chemical Society and is an editor for “Organic Reactions”. He received a B.S in chemistry from Duke University and a Ph.D. in organic chemistry from the University of California, Berkeley.

Positions